Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
Min Zhuo, Chelsea E. Hawley, Julie M. Paik, et al.
JAMA Network Open (2021) Vol. 4, Iss. 10, pp. e2130762-e2130762
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 20
The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
Adam Goldman, Boris Fishman, Gilad Twig, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement
Sukanta Roy, Arya Ghosh, Ankit Majie, et al.
Phytomedicine (2024) Vol. 129, pp. 155638-155638
Closed Access | Times Cited: 13
The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation
Yun‐Yu Chen, Hao‐Chih Chang, Yenn‐Jiang Lin, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 2
Open Access | Times Cited: 10
Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects
Harsh Durgia, Rajan Palui, Jayaprakash Sahoo, et al.
Indian Journal of Endocrinology and Metabolism (2025) Vol. 29, Iss. 1, pp. 32-38
Open Access | Times Cited: 1
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
Marc Evans, Angharad R. Morgan, Sarah Davies, et al.
Age and Ageing (2022) Vol. 51, Iss. 10
Open Access | Times Cited: 29
The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
Bingzi Dong, Ruolin Lv, Jun Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 24
Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
Eveline P. van Poelgeest, M. Louis Handoko, Majon Muller, et al.
European Geriatric Medicine (2023) Vol. 14, Iss. 4, pp. 659-674
Open Access | Times Cited: 15
Effectiveness and safety of empagliflozin: final results from the EMPRISE study
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1328-1342
Closed Access | Times Cited: 5
SGLT2 Inhibitors and Safety in Older Patients
Rena Pollack, Avivit Cahn
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 635-643
Closed Access | Times Cited: 22
Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Andrea Cowan, Nivethika Jeyakumar, Yuguang Kang, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 6, pp. 835-842
Open Access | Times Cited: 19
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
Soo Lim, Seung‐Hwan Lee, Kyung‐Wan Min, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2188-2198
Open Access | Times Cited: 4
Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control
Xuanchen Liu, Mo Wang, Bin Xu, et al.
Journal of Advanced Research (2025)
Open Access
Risk of Fall-Related Injuries Associated with Antidepressant Use in Elderly Patients: A Nationwide Matched Cohort Study
Yu-Seon Jung, David Suh, Hangseok Choi, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 4, pp. 2298-2298
Open Access | Times Cited: 18
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Rong Xu, Difei Lian, Yan Xie, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 7, pp. 134-134
Open Access | Times Cited: 10
Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
Hwa Yeon Ko, Sungho Bea, Han Eol Jeong, et al.
JAMA Network Open (2023) Vol. 6, Iss. 9, pp. e2335797-e2335797
Open Access | Times Cited: 10
Evaluation of the Effect of Sodium-Glucose Cotransporter 2 Inhibition on Fracture Risk: Evidence From Mendelian Randomization and Genetic Association Study
Huajie Dai, Longyi Zheng, Zheng Zhu, et al.
Journal of Bone and Mineral Research (2023) Vol. 38, Iss. 11, pp. 1645-1653
Open Access | Times Cited: 9
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Rikke Viggers, Nicklas H. Rasmussen, Peter Vestergaard
JBMR Plus (2023) Vol. 7, Iss. 11
Open Access | Times Cited: 9
SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors
George S. Q. Tan, Jedidiah I Morton, Stephen Wood, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 6, pp. 1304-1315
Open Access | Times Cited: 3
Mediating the Role of Perceived Social Support Between Frailty and Self-Perceived Burden in Elderly Patients with Diabetes
Mingzhu Chen, Xiaolei Chen, Qin Xu, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 745-752
Open Access | Times Cited: 3
Unleashing frailty from laboratory into real world: A critical step toward frailty‐guided clinical care of older adults
Dae Hyun Kim
Journal of the American Geriatrics Society (2024) Vol. 72, Iss. 11, pp. 3299-3314
Closed Access | Times Cited: 3
Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality
Monika Martiniaková, Vladimíra Mondočková, Veronika Kováčová, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Abhishek Kansara, Faiza Mubeen, Jawairia Shakil
Methodist DeBakey Cardiovascular Journal (2022) Vol. 18, Iss. 4, pp. 62-72
Open Access | Times Cited: 13
Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong
David Tak Wai Lui, Tingting Wu, Eric Ho Man Tang, et al.
Diabetes Research and Clinical Practice (2023) Vol. 197, pp. 110576-110576
Closed Access | Times Cited: 7
Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data
Jorge Balaguer Germán, Marcelino Cortés, Carlos Rodríguez López, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1507-1507
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top